Amgen Stock News

Amgen said on ‌Wednesday its ​experimental ​drug showed ⁠sustained ​reduction in ​disease activity in ​a ​late-stage study ‌of ⁠patients with Sjogren's ​disease, ​an ⁠autoimmune condition.

Amgen unveiled test results Wednesday that suggest it could have one of the first immune-modulating treatments for Sjogren's disease.

Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from the Phase 3 OASIZ-301 study of dazodalibep, the only global Phase 3 trial to demonstrate clinically meaningful improvements in systemic disease a...

Independent VESALIUS-CV Analysis Finds Repatha Highly Cost-Effective in High-Risk Patients Without a Prior Heart Attack or Stroke Long-Term FOURIER External-Control Analysis Shows Repatha Associated With 29% Lower Risk of Major Cardiovascular Events in Patients Living With ASCVD THOUSAND OAKS, Calif., Nov. 9, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data at the American Hea...

Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe  Study Examined More Than Half a Million Adults Living with Heart Disease Results Provide Important New Clinical Evidence to Inform Non-Statin Treatment Decisions for Patients  THOUSAND OAKS, Calif., Nov. 5, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from a larg...

THOUSAND OAKS, Calif., Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2026.

THOUSAND OAKS, Calif., Oct. 26, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of David W.